Scholar Rock Holding Corp (NASDAQ:SRRK) is set to release its Q3 2024 earnings on Nov 12, 2024. The consensus estimate for Q3 ...

November 12, 2024--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing ...

Scholar Rock Holding ( (SRRK) ) has released its Q3 earnings. Here is a breakdown of the information Scholar Rock Holding presented to its ...

Scholar Rock Holding (SRRK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Etzer Darout from BMO Capital reiterated a Buy rating on the ...

Scholar Rock Holding Co. (NASDAQ:SRRK – Get Free Report) has been given a consensus rating of “Buy” by the seven brokerages ...

Good morning and welcome to Scholar Rock's Third Quarter 2024 Financial Results and Business Update Call. All participants will be in listen-only mode. After the company’s prepared remarks all ...

Data support that Scholar Rock’s unique approach to selective myostatin inhibition could improve body composition in people living with obesity and on an existing background treatment - Scholar ...

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases ...

Poster presentation to include new safety, efficacy, and biomarker data from the long-term expansion phase of the DRAGON trial in patients with advanced solid tumors treated with SRK-181 Scholar Rock ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA ...

Scholar Rock (SRRK) announced new preclinical data that support the potential of SRK-439, a highly selective investigational antimyostatin antibody, to increase lean mass and lower fat mass gain ...